Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets

被引：16

作者：

Ding, Ya-Hui ^{[1
,3
]}

Ma, Yuan ^{[1
,3
]}

Qian, Lin-Yan ^{[1
,3
]}

Xu, Qiang ^{[1
,3
]}

Wang, Li-Hong ^{[1
,3
]}

Huang, Dong-Sheng ^{[2
,3
]}

Zou, Hai ^{[1
,3
]}

机构：

[1] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou 310014, Zhejiang, Peoples R China

[2] Zhejiang Prov Peoples Hosp, Dept Hepatobiliary Surg, Hangzhou 310014, Zhejiang, Peoples R China

[3] Hangzhou Med Coll, Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China

来源：

ONCOTARGET | 2017年 / 8卷 / 36期

关键词：

non-alcoholic fatty liver disease; atrial fibrillation; adiponectin; insulin resistance; renin angiotensin aldosterone system; CORONARY-HEART-DISEASE; CIRCULATING ADIPONECTIN LEVELS; ANGIOTENSIN-CONVERTING ENZYME; MOLECULAR-WEIGHT ADIPONECTIN; INCREASED ENERGY-EXPENDITURE; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC STEATOSIS; OXIDATIVE STRESS; DIABETES-MELLITUS;

D O I：

10.18632/oncotarget.19522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.

引用

页码：60673 / 60683

页数：11

共 50 条

[31] Helicobacter pylori, non-alcoholic liver disease and atrial fibrillation: Is there a link?
Cai, Xiaoyan
Zheng, Sulin
Zhang, Yan
Huang, Yuli
LIVER INTERNATIONAL, 2020, 40 (08) : 2037 - 2038
[32] The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway
Lv, Juan
Xing, Chunlei
Chen, Yuhong
Bian, Huihui
Lv, Nanning
Wang, Zhibin
Liu, Mingming
Su, Li
PHARMACEUTICALS, 2022, 15 (10)
[33] Non-alcoholic Fatty Liver Disease
Tan, Hui-Hui
Chang, Jason Pik-Eu
PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
[34] Non-alcoholic fatty liver disease
Angulo, P
Lindor, KD
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
[35] Non-alcoholic fatty liver disease
Powell, Elizabeth E.
Wong, Vincent Wai-Sun
Rinella, Mary
LANCET, 2021, 397 (10290): : 2212 - 2224
[36] Non-alcoholic fatty liver disease
Maurice, James
Manousou, Pinelopi
CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
[37] Non-alcoholic fatty liver disease
Neuschwander-Tetri, Brent A.
BMC MEDICINE, 2017, 15
[38] Non-alcoholic fatty liver disease
Smith, Briohny W.
Adams, Leon A.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
[39] Non-alcoholic fatty liver disease
Carreras, MP
Tortajada, GC
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
[40] Non-alcoholic fatty liver disease
Bjornsson, Einar
Angulo, Paul
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030

← 1 2 3 4 5 →